With encouraging data from a phase I trial in amyotrophic lateral sclerosis (ALS) and a phase II trial under way testing NSI-566, Neuralstem Inc. has begun – with the same candidate – the first human neural stem cell study to be given the FDA's nod for chronic spinal cord injury. Read More
Arrowhead Research Corp.'s shares (NASDAQ:ARWR) regained little ground Thursday after hitting a 52-week low at midweek as investors sold off shares over concern about the potential performance and timing of the company's experimental RNAi-based chronic hepatitis B (HBV) therapy, Read More
Enterovirus D68 has been around for decades, but this year it has seen a record-breaking number of infections. That surge, perhaps in combination with a general anxiety about infectious diseases nourished by threats like the West African Ebola outbreak, has the general public worried about a homegrown epidemic threat. Read More
SHANGHAI – European drug companies may find it hard to bend the ear of the Chinese government on their own. The country is large with numerous stakeholders to take into account as China undertakes its massive health care reform project. Read More
Biotime Inc., of Alameda, Calif., closed the equity financing it disclosed on Oct. 3, through which Biotime received about $29 million and certain subsidiaries received about $1.5 million. Read More
Bravovax Co. Ltd., of Wuhan, China, sublicensed rights to rotavirus vaccine candidate RRV-TV from the International Medica Foundation, of Rochester, Minn. Read More
Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J. reported that an independent data and safety monitoring board (DSMB) for the company's phase III study in acute myeloid leukemia (AML), called SEAMLESS, has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. Read More
Shire plc, of Dublin, said it received further guidance from the FDA on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts), an investigational oral stimulant medication being evaluated as a potential treatment for attention deficit hyperactivity disorder in adults. Read More
